Cytokines required for induction of histocompatibility leukocyte antigen-class I-restricted and tumor-specific cytotoxic T lymphocytes by a SART1-derived peptide

Japanese Journal of Cancer Research

Volumn 90, Issue 9, 1999, Pages 1007-1015

  Matsunaga, Kazuko ^a   Nakao, Masanobu ^a   Masuoka, Kazuhiro ^b   Inoue, Yoshiko ^a   Gouhara, Rumi ^b   Imaizumi, Toshihiro ^a   Nishizaka, Shinya ^a   Itoh, Kyogo ^a,b  

^a KURUME UNIVERSITY   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer vaccine; Cytokine; Cytotoxic T lymphocyte; SART1 antigen

Indexed keywords

ALPHA INTERFERON; COLONY STIMULATING FACTOR 1; CYTOKINE; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4;

ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; LEUKOCYTE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MONONUCLEAR CELL; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0032726726     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1999.tb00849.x     Document Type: Article

References (37)

1. Traversari, C., van der Bruggen, P., Luescher, I. F., Lurquin, C., Chomez, P., van Pel, A., de Plaen, E., AmarCostesec, A. and Boon, T. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med., 176, 1453-1475 (1992).
2. van der Bruggen, P., Bastin, J., Gajewski, T., Coulie, P. G., Boel, P., de Smet, C., Traversari, C., Townsend, A. and Boon, T. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol., 24, 3038-3043 (1994).
3. Kawakami, Y., Eliyaku, S., Sakaguchi, K., Robbins, P. F., Rivoltini, L., Yannelli, J. R., Appella, E. and Rosenberg, S. A. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med., 180, 347-352 (1994).
4. Kawakami, Y., Eliyaku, S., Jennings, C., Sakaguchi, K., Kang, X., Southwood, S., Robbins, P. F., Sette, A., Appella, E. and Rosenberg, S. A. Recognition of multiple epitopes in the human melanoma antigen gp 100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol., 154, 3961-3968 (1995).
5. Kang, X., Kawakami, Y., El-Gamil, M., Wang, R., Sakaguchi, K., Yanneli, E., Appella, E., Rosenberg, S. A. and Robbins, P. F. Identification of a tyrosinase epitope recognized by HLA-A24-restricted tumor-infiltrating lymphocytes. J. Immunol., 155, 1343-1348 (1995).
6. Robbins, P. F., El-Gamil, M., Li, Y. F., Topalian, S. L., Rivoltini, L., Sakaguchi, K., Appella, E. and Rosenberg, S. A. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-reslricted tumor-infiltrating lymphocytes. J. Immunol., 154, 5944-5950 (1995).
7. Robbins, P. F., El-Gamil, M., Li, Y. F., Kawakami, Y., Loftus, D., Appella, E. and Rosenberg, S. A. A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med., 183, 1185-1192 (1996).
8. Robbins, P. F., El-Gamil, M., Li, Y. F., Fitzgerrald, E. B., Kawakami, Y. and Rosenberg, S. A. The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. J. Immunol., 159, 303-308 (1997).
9. Marchand, M., Weynants, P., Rankin, E., Arienti, F., Belli, F., Parmiani, G., Cascinelli, N., Bourlond, A., Vanwijck, R., Humblet, Y., Canon, J. L., Laurent, C., Naeyaert, J. M., Plagne, R., Draemaeker, R., Knuth, A., Jager, E., Brassur, F., Herman, J., Coulie, P. G. and Boon, T. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer, 63, 883-885 (1995).
10. Rosenberg, S. A., Yang, J. C., Schwartzenruber, D. J., Hwu, P., Marincola, F. M., Topalain, S. L., Restifo, N. P., Dudley, M. E., Schwart, S. L., Spiess, P. J., Wunderlich, J. R., Parkhurst, M. A., Kawakami, Y., Seipp, C. A., Einhorn, J. H. and White, D. E. Immunologic and therapeutic evaluation of synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med., 4, 321-328 (1998).
11. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G. and Schadendorf, D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med., 4, 328-332 (1998).
12. Shichijo, S., Nakao, M., Imai, Y., Takasu, H., Kawamoto, M., Niiya, F., Yang, D., Toh, Y., Yamana, H. and Itoh, K. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J. Exp. Med., 187, 277-288 (1998).
13. Kikuchi, K., Nakao, M., Inoue, Y., Matsunaga, K., Shichijyo, S. and Itoh, K. Identification of a SART-1-derived peptide capable of inducing the HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes. Int. J. Cancer, 81, 459-466 (1999).
14. Mandruzzato, S., Brasseur, F., Andry, G., Boon, T. and van der Bruggen, P. A. CASP-8 mutation recognized by cytolytic lymphocytes on a human head and neck carcinoma. J. Exp. Med., 186, 785-793 (1997).
15. Jager, E., Chen, Y. T., Drijfhout, J. W., Karbach, J., Ringhoffer, M., Jager, D., Arand, M., Wada, H., Noguchi, Y., Stockert, E., Old, L. J. and Knuth, A. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO1-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitope. J. Exp. Med., 18, 265-270 (1998).
16. Terres, G. and Coffman, R. L. The role of IL-4 and IL-10 cytokines in controlling an anti-tumor response in vivo. Int. Immunol., 10, 823-832 (1998).
17. Wang, T. and Chen, W. Evaluation of the antitumor activity of human IL-4 by in vitro and in vivo assays. Chin. Med. Sci. J., 9, 248-254 (1994).
18. Wang, L., Goillot, E. and Tepper, R. I. IL-10 inhibits alloreactive cytotoxic T lymphocyte generation in vivo. Cell. Immunol., 159, 152-169 (1994).
19. Matsuda, M., Salazar, F., Masucci, G., Hansson, J., Pisa, P., Zhang, Q.-J., Masucci, M. G. and Kiessling, R. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J. Exp. Med., 180, 2371-2376 (1994).
20. de waal Malefyt, R., Haanen, J., Spits, H., Ronvarolo, M.-G., te Velde, A., Figdor, C., Johnson, K., Kastelein, R., Yssel, H. and de Vries, J. E. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via down regulation of class II major histocompatibility complex expression. J. Exp. Med., 174, 915-924 (1991).
21. Taga, K. and Tosato, G. IL-10 inhibits human T cell proliferation and IL-2 production. J. Immunol., 148, 1143-1148 (1992).
22. Kawakami, Y., Rosenberg, S. A. and Lotze, M. T. Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. J. Exp. Med., 168, 2183-2191 (1988).
23. Roth, A. D., Dupuis, S. and Alberto, P. Human recombinant IL-4 decreases the emergence of non-specific cytolytic cells and favours the appearance of memory cells (CD4+CD45RO+) in the IL-2-driven development of cytotoxic T lymphocytes against autologous ovarian tumor cells. Clin. Exp. Immunol., 101, 362-368 (1995).
24. Salmeron, M. A., Balch, C. M., Ross, M. I. and Itoh, K. Role of uncultured human melanoma cells in the proliferation of autologous tumor-specific cytotoxic T lymphocytes. Cell. Immunol., 143, 228-237 (1992).
25. Tanaka, F., Fujie, T., Tahara, K., Mori, M., Takesako, K., Sette, A., Celis, E. and Akiyoshi, T. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24. Cancer Res., 57, 4465-4468 (1997).
26. Taz, Z. and Rosenberg, S. A. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic lymphocytes that fail to recognize HER-2/ neu+ tumors. Cancer Res., 58, 4902-4908 (1998).
27. Tjandrawan, T., Martin, D. A., Maeurer, M. J., Castelli, C., Lotze, M. T. and Storkus, W. J. Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro. J. Immunother., 21, 149-157 (1998).
28. Romani, N., Gruner, S., Brang, D., Kämpgen, E., Lenz, A., Trockenbacher, B., Konwalinka, G., Fritsch, P. O., Steinman, R. M. and Schuler, G. Proliferating dendritic cell progenitors in human blood. J. Exp. Med., 180, 83-93 (1994).
29. Yanagihara, S., Komura, E., Nagafune, J., Watarai, H. and Yamaguchi, Y. EBI1/CCR7 is a new member of dendritic cell chemokine receptor that is up-regulated upon maturation. J. Immunol., 161, 3096-3102 (1998).
30. Man, X, Itoh, K., Balch, C. M. and Pellis, N. R. Recombinant interleukin 4 (rIL4) inhibits interleukin 2 induced activation of peripheral blood lymphocytes. Lymphokine Res., 7, 227-235 (1988).
31. Travesari, C., Meazza, R., Coppolecchia, M., Basso, S., Verrecchia, A., van der Brunggen, P., Ardzzoni, A., Gaggero, A. and Ferrini, S. IFN-γ gene transfer restores HLA-class I expression and MAGE-3 antigen presentation to CTL in HLA-deficient small cell lung cancer. Gene Ther., 4, 1029-1035 (1997).
32. Selinger, B., Dunn, T., Schwenzer, A., Casper, J., Huber, C. and Schmoll, H. J. Analysis of the MHC class I antigen presentation machinery in human embryonal carcinomas: evidence for deficiencies in TAP, LMP and MHC class I expression and their upregulation by IFN-γ. Scand. J. Immunol., 46, 625-632 (1997).
33. Selinger, B., Hammers, S., Höhne, A., Zeidler, R., Knuth, A., Gerharz, C.-D. and Huber, C. IFN-γ-mediated coordinated transcriptional regulation of the human TAP-1 and LMP-2 genes in human renal cell carcinoma. Clin. Cancer Res., 3, 573-578 (1997).
34. Alexander-Miller, M. A., Leggatt, G. R., Sarin, A. and Berzofsky, J. A. Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J. Exp. Med., 184, 485-492 (1996).
35. Sugita, S., Sagawa, K., Mochizuki, M., Shichijo, S. and Itoh, K. Melanocyte lysis by cytotoxic T lymphocytes recognizing the MART-1 melanoma antigen in HLA-A2 patients with Vogt-Koyanagi-Harada disease. Int. Immunol., 8, 799-803 (1996).
36. Romani, L. The T cell response against fungal infections. Curr. Opin. Immunol., 9, 484-490 (1997).
37. Rissoan, M.-C., Soumelis, V., Kadowaki, N., Grouard, G., Briere, F., Malefyt, R. de W. and Liu, Y.-J. Reciprocal control of T helper cell and dendritic cell differentiation. Science, 283, 1183 -1186 (1999).